LOW DOSE REGIMEN AND FORMULATION OF A 5-METHYL-1,2,4-OXADIAZOL-3-YL COMPOUND
The present invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenera...
Saved in:
Main Authors | , |
---|---|
Format | Patent |
Language | English |
Published |
26.10.2023
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The present invention provides a compound of Formula I:or a pharmaceutically acceptable salt thereof, wherein the compound of Formula I, or pharmaceutically acceptable salt thereof is administered orally with a total dose of the compound of 0.1 mg/day to 5 mg/day, useful for treating a neurodegenerative disease, including neurodegenerative tauopathies, such as Alzheimer's disease, frontotemporal dementia, corticobasilar syndrome, and progressive supranuclear palsy. |
---|---|
Bibliography: | Application Number: US202118005245 |